Arix Bioscience - Interview with VelosBio CEO

Dave Johnson, CEO of VelosBio, discusses how VelosBio is developing novel anti-body drug conjugates to target sold tumours.

Arix Bioscience
Management Team

Company Events - ARIX BIOSCIENCE